Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
opioid |
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
gptkb:N07BB04
|
| gptkbp:CASNumber |
58895-64-0
|
| gptkbp:developedBy |
gptkb:Lundbeck
|
| gptkbp:eliminationHalfLife |
12.5 hours
|
| gptkbp:hasMolecularFormula |
C21H25NO3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nalmefene
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
mu-opioid receptor antagonist
delta-opioid receptor partial agonist kappa-opioid receptor partial agonist |
| gptkbp:proteinBinding |
30%
|
| gptkbp:relatedTo |
gptkb:Naltrexone
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
nausea
dizziness fatigue headache insomnia |
| gptkbp:usedFor |
alcohol dependence
opioid overdose reversal |
| gptkbp:bfsParent |
gptkb:Opioids
|
| gptkbp:bfsLayer |
7
|